Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 20, 2017updated 25 Oct 2017 10:55am

Shanghai Pharma provides update on reports about Cardinal Health deal

Shanghai Pharmaceuticals has issued a clarification on media reports about its acquisition of Cardinal Health’s pharmaceutical distribution business in China.

Shanghai Pharmaceuticals has issued a clarification on media reports about its acquisition of Cardinal Health’s pharmaceutical distribution business in China.

The firm informed that the submission of first and second rounds of bids for the potential acquisition of Cardinal China occurred on 21 July and 15 September of this year, respectively.

Shanghai further noted that the second round is still at the non-exclusive bidding stage and has uncertainties.

Details of the bidding process and terms such as bidding price, Cardinal China’s operational and financial conditions have not been divulged due to confidentiality requirements.

Cardinal China business comprises national drugs and medical devices distribution, hospital direct sales, special drugs, specialist pharmacies and commercial technology segments.

“Cardinal China business comprises national drugs and medical devices distribution, hospital direct sales, special drugs, specialist pharmacies and commercial technology segments.”

The company’s distribution network, which caters to 322 cities and around 11, 000 medical organisations, includes 14 hospital direct sales firms, 17 distribution centres and 30 DTP pharmacies.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Last year, Cardinal’s main business income in the country was reported to be approximately CNY25.4bn ($3.83bn).

The acquisition is in line with Shanghai’s strategic goal to expand distribution, accelerate national layout and improve service contents.

Shanghai expects that upon completion, the transaction would bolster its footprint in pharmaceutical distribution industry of China, including import products agency, professional third-party pharmaceutical logistics, DTP pharmacies and distribution of medical devices.

In addition to the assessment of Cardinal China’s business development in the future, the acquisition proposals are subject to further negotiations between the parties following the selection and acceptance of relevant submissions from the bidders.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU